Selah Mapes
About Selah Mapes
Selah Mapes is the Associate Director of ERP Business Process Integration for Cell Therapy at Bristol Myers Squibb, with over fifteen years of experience in biotech quality assurance and supply chain.
Company
Selah Mapes currently works at Bristol Myers Squibb, a global biopharmaceutical company. She holds the position of Associate Director, ERP Business Process Integration, Cell Therapy, in the Seattle, Washington office. Prior to this, she spent a significant portion of her career at Genentech, Inc., a biotechnology company known for its development of innovative treatments.
Title
Selah Mapes is the Associate Director of ERP Business Process Integration, Cell Therapy at Bristol Myers Squibb. She started in this role in August 2021 and works out of the Seattle, Washington office, despite being based in Redwood City, California.
Education and Expertise
Selah Mapes studied Industrial Engineering at the University of Southern California, graduating in 2000. She has accumulated over fifteen years of experience in the biotech industry, specifically in Quality Assurance and Supply Chain. She is well-versed in quality processes, including master data management, change control, discrepancy management, and systems validation. She is also experienced with GMP systems such as SAP, Trackwise, and EDMS.
Background
Selah Mapes has a long history in the biotech sector. Before joining Bristol Myers Squibb, she worked at Genentech, Inc. for almost two decades. Her roles at Genentech included Quality Assurance Associate, Technical Manager for Quality Assurance and Quality Systems and Processes, and Senior Business Analyst for SAP QM. Her responsibilities spanned various quality-related areas, enhancing her expertise in compliance and system integration.
Achievements
Selah Mapes has progressed through several key roles in the biotech industry, showcasing her capabilities in quality assurance and process integration. In her current role at Bristol Myers Squibb, she integrates ERP business processes for cell therapy, contributing to the company's advancements in this specialized field.